Proton pump inhibitors associated with rapid eye movement sleep behaviour disorder
- PMID: 34972777
- PMCID: PMC8720946
- DOI: 10.1136/bcr-2021-246469
Proton pump inhibitors associated with rapid eye movement sleep behaviour disorder
Abstract
We present the case of a 65-year-old woman diagnosed with rapid eye movement sleep behaviour disorder (REMBD) based on typical symptoms and confirmed with an inpatient polysomnogram. She was prescribed clonazepam and later temazepam but continued to have intrusive symptoms. She subsequently recalled that the onset of dream enactment coincided with starting high-dose omeprazole for acid reflux. With this insight, she stopped the omeprazole. Within days, the dream enactment and nocturnal movements subsided. She stopped taking the temazepam and was symptom free for a few months. However, she was started on lansoprazole for recurrent dyspepsia. Once again she experienced violent movements in sleep. This is the first time an association between proton pump inhibitors (PPIs) and REMBD has been reported. PPIs have many effects on the central nervous system and should be considered as a possible provoking factor in people presenting with REMBD.
Keywords: sleep disorders (respiratory medicine); unwanted effects / adverse reactions.
© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Figures
Similar articles
-
Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.Scand J Gastroenterol. 1998 Dec;33(12):1239-43. doi: 10.1080/00365529850172304. Scand J Gastroenterol. 1998. PMID: 9930385 Clinical Trial.
-
Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.Am J Med. 2004 Sep 6;117 Suppl 5A:14S-22S. doi: 10.1016/j.amjmed.2004.07.020. Am J Med. 2004. PMID: 15478848 Review.
-
Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.Aliment Pharmacol Ther. 1998 Dec;12(12):1231-4. doi: 10.1046/j.1365-2036.1998.00419.x. Aliment Pharmacol Ther. 1998. PMID: 9882031 Clinical Trial.
-
Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.Eur J Gastroenterol Hepatol. 1998 Sep;10(9):753-8. doi: 10.1097/00042737-199809000-00005. Eur J Gastroenterol Hepatol. 1998. PMID: 9831269 Clinical Trial.
-
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.Clin Pharmacokinet. 1996 Nov;31(5):386-406. doi: 10.2165/00003088-199631050-00005. Clin Pharmacokinet. 1996. PMID: 9118586 Review.
Cited by
-
Multidimensional Assessment of Psychiatric Adverse Events Related to Proton Pump Inhibitors: A Real-World, Pharmacovigilance Study.CNS Neurosci Ther. 2025 May;31(5):e70436. doi: 10.1111/cns.70436. CNS Neurosci Ther. 2025. PMID: 40365732 Free PMC article.
References
-
- Bassetti CL, Dogas Z, Peigneux P. Physiological basis of sleep, sleep medicine textbook, European sleep research Society, 2014: 1–13.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical